

Translation

Notice: This document is a translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

July 1, 2025

To Whom It May Concern:

Company Name: Daito Pharmaceutical Co., Ltd.
Representative: Hiroshi Matsumori, President and CEO
(Securities Code: 4577, Prime Market of Tokyo Stock Exchange)
Inquiries: Kenji Otsuga, CFO
(Telephone Number: +81-76-421-5665)

Notice Regarding the Completion of Cancellation of Treasury Shares
(Cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act)

Daito Pharmaceutical Co., Ltd. (the “Company”) hereby announces that the Company completed the cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act on June 30, 2025, as resolved by the Board of Directors at a meeting on January 10, 2025.

- | | |
|------------------------------------|--|
| 1. Class of shares canceled | Common stock |
| 2. Total number of shares canceled | 600,000 shares (300,000 before stock split)*1
(2.0% of total shares issued before cancellation) |
| 3. Cancellation date | June 30, 2025 |

(Reference)

Total number of shares issued after cancellation 30,096,880 shares
Number of treasury shares after cancellation 16,434shares*2

*1 The Company conducted a 2-for-1 split of common shares on June 1, 2025

*2 The number of treasury shares following the above cancellation does not include the 94,340 shares of the Company held in trust under the stock delivery trust for Board Directors (excluding Board Directors who are Audit and Supervisory Committee Members and Outside Directors).

End